Amatuximab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg IV amatuximab once weekly with IV pemetrexed and IV cisplatin gi...